All In Biotech

NDA 021612 · Cipher Pharms INC

Lipofen

Fenofibrate · Oral

Last checked: Nov 20, 2026Latest source record: Jun 6, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Jan 11, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

211

64 Phase 3, 15 recruiting

FAERS reports

35,744

24,452 serious, 2,830 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • LIPOFEN · FENOFIBRATE 100MG · CAPSULE, ORAL · Discontinued
  • LIPOFEN · FENOFIBRATE 150MG · CAPSULE, ORAL · Prescription
  • LIPOFEN · FENOFIBRATE 50MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fenofibrate" as an intervention, any sponsor and status, largest first.

All 211 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue2,198
  • diarrhoea2,137
  • nausea2,068
  • drug ineffective1,825
  • headache1,581
  • dyspnoea1,552
  • off label use1,415
  • dizziness1,401
  • pain1,395
  • fall1,382
  • asthenia1,331
  • acute kidney injury1,282

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004264
2005251
2006397
2007300
2008474
2009564
2010677
2011981
20121,105
20131,062
20141,370
20152,187
20162,574
20172,504
20182,793
20192,719
20202,495
20212,265
20222,230
20232,161
20242,070
20252,334
20261,967

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lipofen (Fenofibrate)

2024 spending

$168K

Beneficiaries

87

279 claims

Per beneficiary

$1,926

$8.90 per unit

View as table
YearSpending
2020$0
2021$34,318
2022$224,358
2023$205,112
2024$167,539

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 589 on PubMed

Sponsor: Cipher Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.